



NOTICE OF APPEAL

15 January 2026, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) (**Mayne Pharma**) refers to its announcement on 16 October 2025 relating to the judgment delivered on 15 October 2025 in which the Supreme Court of New South Wales found in favour of Mayne Pharma and its announcement on 10 November 2025 regarding a notice of intention to appeal filed by Cosette Pharmaceuticals, Inc. (**Cosette**) and its BidCo.

Mayne Pharma has today received a notice of appeal filed by Cosette and its BidCo with the Supreme Court of New South Wales, Court of Appeal.

The two grounds set out in the notice of appeal seek to challenge various of the Court's findings related to:

1. Mayne Pharma's FY25 EBITDA the subject of Cosette's misleading and deceptive conduct claim; and
2. Cosette's allegation that a Mayne Material Adverse Change had occurred on the basis of Cosette's pleaded Q3 FY25 Sales Performance Matters.

Mayne Pharma is considering the notice of appeal and intends to vigorously defend the appeal.

- ENDS -

Authorised for release to the ASX by the Board Chair

For further information contact:

Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals to offer patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40 year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.

Mayne Pharma Group Limited

ABN 76 115 832 963

maynepharma.com

1538 Main North Road, Salisbury South, SA 5106 Australia

